Vermillion, Inc. and its subsidiaries engage in the discovery, development, and commercialization of diagnostics tests that help physicians to diagnose and treat patients. The company develops novel diagnostic tests in the fields of oncology, hematology, cardiology, and women's health with the initial focus on ovarian cancer. Its lead product includes the OVA1 ovarian tumor triage test (the 'OVA1 Test'), which addresses pre-surgical identification of women who are at high risk of having a malignant ovarian tumor. The company has collaborations with various academic and research institutions, including The Johns Hopkins University School of Medicine; The University of Texas M.D. Anderson Cancer Center; University College London; The University of Texas Medical Branch; The Katholieke Universiteit Leuven; Clinic of Gynecology and Clinic of Oncology, Rigshospitalet; Copenhagen University Hospital; The Ohio State University Research Foundation; Stanford University; and the University of Kentucky. It also has strategic alliance agreement with Quest Diagnostics Incorporated to develop and commercialize up to three diagnostic tests. Vermillion, Inc. serves clinical reference laboratories, hospital laboratories, and physician offices. The company was formerly known as Ciphergen Biosystems, Inc. and changed its name to Vermillion, Inc. in August 2007. Vermillion, Inc. was founded in 1993 and is headquartered in Austin, Texas.